Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2018

Open Access 01-12-2018 | Case report

Ivermectin-induced fixed drug eruption in an elderly Cameroonian: a case report

Authors: Calypse Asangbe Ngwasiri, Martin Hongieh Abanda, Leopold Ndemnge Aminde

Published in: Journal of Medical Case Reports | Issue 1/2018

Login to get access

Abstract

Background

Cutaneous adverse reactions to medications are extremely common and display characteristic clinical morphology. A fixed drug eruption is a cutaneous adverse drug reaction due to type IV or delayed cell-mediated hypersensitivity. Ivermectin, a broad-spectrum anti-parasitic compound, has been an essential component of public health campaigns targeting the control of two devastating neglected tropical diseases: onchocerciasis (river blindness) and lymphatic filariasis.

Case presentation

We report the case of a 75-year-old Cameroonian man of the Bamileke ancestry who developed multiple fixed drug eruptions a few hours following ivermectin intake that worsened with repeated drug consumption. Discontinuation of the drug, counselling, systemic steroids, and orally administered antihistamines were the treatment modalities employed. Marked regression of the lesions ensued with residual hyperpigmentation and dyschromia.

Conclusion

Keen observation on the part of physicians is mandatory during the administration of ivermectin for quick recognition and prevention of this adverse drug reaction.
Literature
1.
go back to reference Ratinder J, Dinesh P, Deepa C. Fixed drug eruption due to levocetirizine. J Pharmacol Pharmacother. 2016;7(2):109–11.CrossRef Ratinder J, Dinesh P, Deepa C. Fixed drug eruption due to levocetirizine. J Pharmacol Pharmacother. 2016;7(2):109–11.CrossRef
2.
go back to reference Akyazi H, Mungan S, Kara IH. Naproxen-induced fixed drug eruption: a case report. Hum Exp Toxicol. 2011;30(11):1872–4.CrossRefPubMed Akyazi H, Mungan S, Kara IH. Naproxen-induced fixed drug eruption: a case report. Hum Exp Toxicol. 2011;30(11):1872–4.CrossRefPubMed
3.
go back to reference Gupta S, Gupta S, Mittal A, David S. Oral fixed drug eruption caused by gabapentin. J Eur Acad Dermatol Venereol. 2009;23:1207–8.CrossRefPubMed Gupta S, Gupta S, Mittal A, David S. Oral fixed drug eruption caused by gabapentin. J Eur Acad Dermatol Venereol. 2009;23:1207–8.CrossRefPubMed
5.
go back to reference Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of recent literature. Drug Saf. 2007;30(5):379–407.CrossRefPubMed Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of recent literature. Drug Saf. 2007;30(5):379–407.CrossRefPubMed
6.
go back to reference Spear R, Durrheim D. Mass treatment with ivermectin: an underutilized public health strategy. Bull World Health Organ. 2004;82:559–636. Spear R, Durrheim D. Mass treatment with ivermectin: an underutilized public health strategy. Bull World Health Organ. 2004;82:559–636.
7.
go back to reference WHO. Prevention, control and elimination of onchocerciasis control: progress report, 2013–2014. Wkly Epidemiol Rec. 2014;374(49):545–60. WHO. Prevention, control and elimination of onchocerciasis control: progress report, 2013–2014. Wkly Epidemiol Rec. 2014;374(49):545–60.
8.
9.
go back to reference Egerton JR, et al. 22, 23-Dihydroavermectin B1a, a new broad-spectrum antiparasitic agent. Br Vet J. 1980;136:88–97.CrossRefPubMed Egerton JR, et al. 22, 23-Dihydroavermectin B1a, a new broad-spectrum antiparasitic agent. Br Vet J. 1980;136:88–97.CrossRefPubMed
10.
12.
go back to reference Veit O, Beck B, Steuerwald M, Hatz C. First case of ivermectin-induced severe hepatitis. Trans R Soc Trop Med Hyg. 2006;100(8):795–7.CrossRefPubMed Veit O, Beck B, Steuerwald M, Hatz C. First case of ivermectin-induced severe hepatitis. Trans R Soc Trop Med Hyg. 2006;100(8):795–7.CrossRefPubMed
14.
go back to reference Naranjo CA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefPubMed Naranjo CA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefPubMed
15.
go back to reference Weedon D. The lichenoid reaction pattern (interface dermatitis). Skin pathology. 2nd ed. London: Churchill Livingstone; 2002. p. 42–3. Weedon D. The lichenoid reaction pattern (interface dermatitis). Skin pathology. 2nd ed. London: Churchill Livingstone; 2002. p. 42–3.
16.
go back to reference Lammintausta K, Kortekangas-Savolainen O. Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period. Acta Derm Venereol. 2005;85(6):491–6.PubMed Lammintausta K, Kortekangas-Savolainen O. Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period. Acta Derm Venereol. 2005;85(6):491–6.PubMed
17.
go back to reference Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol. 2005;152(5):968–74.CrossRefPubMed Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol. 2005;152(5):968–74.CrossRefPubMed
Metadata
Title
Ivermectin-induced fixed drug eruption in an elderly Cameroonian: a case report
Authors
Calypse Asangbe Ngwasiri
Martin Hongieh Abanda
Leopold Ndemnge Aminde
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2018
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-018-1801-1

Other articles of this Issue 1/2018

Journal of Medical Case Reports 1/2018 Go to the issue